Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy

Trial Profile

Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms CLARITY-1
  • Most Recent Events

    • 07 May 2017 Primary endpoint (Difference in mean change in best corrected visual acuity measured in ETDRS letter scores from baseline to 52 weeks) has been met, according to the results published in the Internet Document (The Lancet)
    • 07 May 2017 Results published in the Internet Document (The Lancet)
    • 05 Dec 2015 Accrual to date is 105% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top